The combination drove a strong immune response and detectable viremia with no additional toxicity compared with vaccines alone.
Follow-up observational study detects small yet significant CVD risk with 5-year cumulative use of darunavir/ritonavir but no risk with atazanavir/ritonavir.
Although acute HCV incidence declined by 51%, syphilis diagnoses increased by 41% in Dutch public health STD clinics between 2015 and 2016.
No evidence of increased HCC incidence linked to DAA use in this observational Spanish cohort; results may reflect uptick in use of HCV therapy in advanced liver disease.
Efficacy and safety of bictegravir plus TAF/FTC comparable to that of DTG plus TAF/FTC.
After receiving TMC278 LA injections, 68% of participants strongly agreed they would use an injectable prophylaxis in the future.
Ad hoc analysis suggests continued use of cabotegravir plus rilpivirine. following induction-maintenance treatment safe and effective.
Open-label extension phase of women-only WAVES study observed improvement in bone and renal markers with switch to EVG/COBI/FTC/TAF.
Novel monoclonal antibody appears less effective in patients with low baseline CD4+ cell counts.
Two-drug regimen maintained virologic suppression in 95% of patients over 48 weeks and improved bone turnover markers despite increase in low-grade, drug-related adverse events following switch.
Extended follow-up reverses noninferiority previously observed at Week 24.
Efficacy of elsulfavirine plus TDF/FTC comparable to that of EFV plus TDF/FTC but with lower frequency of drug-related AEs and specific CNS events.
EVG/COBI/FTC/TAF continued to be associated with improvements in renal and bone markers vs EVG/COBI/FTC/TDF through 144 weeks.
97% of patients maintained virologic suppression following switch from initial triple-therapy ART to dolutegravir plus lamivudine with a low incidence of serious adverse events.
Doravirine was well tolerated with very low incidence of resistance.
Patient with an acute OI experienced virologic failure on dolutegravir-based therapy followed by subsequent resuppression with ART intensification.
High bone turnover and urinary phosphate wasting could identify patients most likely to benefit from TDF to TAF switch.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.